THC Stock Analysis: Buy, Sell, or Hold?
THC - Tenet Healthcare Corporation New
$176.92
3.75 (2.17%)
▲
5d:
+9.17%
30d:
-9.67%
90d:
-22.28%
BUY
HIGH Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: Jul 28, 2026
Smart Money Accumulation
None View Scanner →
Strength: 7.6/10
Get Alerted When THC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: THC appears deeply undervalued. Market expects -5.5% annual earnings decline despite 88% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: THC appears deeply undervalued. Market expects -5.5% annual earnings decline despite 88% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$56.16
Based on -20.8% avg growth
INTRINSIC VALUE TODAY
$34.87
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: THC is currently trading at $176.92, which is considered slightly low relative to its 30-day fair value range of $167.85 to $192.74. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.8) compared to its historical average (11.6). Remarkably, the market is currently pricing in an annual earnings decline of 5.5% over the next few years. This pessimistic expectation contrasts with the company's recent 87.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, THC is in a downtrend. Immediate support is located at $157.58, while resistance sits at $182.69.
Market Sentiment: THC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $243.62 (+40.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, THC is in a downtrend. Immediate support is located at $157.58, while resistance sits at $182.69.
Market Sentiment: THC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $243.62 (+40.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$167.85 -
$192.74
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 40.7% below Wall St target ($243.62)
Trading Range Analysis
30-Day Trading Range
$167.85 -
$192.74
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$157.58
Resistance Level
$182.69
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.77
Wall Street Target
$243.62
(+40.7%)
Revenue Growth (YoY)
2.8%
Earnings Growth (YoY)
87.6%
Profit Margin
7.9%
Valuation Discount vs History
-5.5% cheaper
PE vs Historical
9.8 vs 11.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.5%
(market-implied from PE analysis)
1-Year Target
$163.65
(-6%)
2-Year Target
$154.65
(-11%)
3-Year Target
$146.14
(-16%)
3-Yr Target (if PE normalizes)
(PE: 10→12)
$173.53
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: -45.7%)
$383.26
(+121%)
Base:
(SPY PE: 9.8, Growth: -45.7%)
$170.81
(-1%)
Bear:
(PE: 8.3, Growth: -45.7%)
$145.19
(-16%)
📈
Valuation based on Current Earnings
Trailing PE: 8.57 | Current EPS (TTM): $19.23
Bull Case
$167.07
(-4%)
Analyst growth -7.8%, PE expands to 9.4
Base Case
$151.88
(-12%)
Market implied -7.8%, PE stable at 8.6
Bear Case
$112.04
(-35%)
Severe decline -20.0%, PE contracts to 7.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.8 to 11.6
Stabilization Target:
$205.62
(+18.7%)
PE Expansion Potential:
+18.7%
Share & Embed Analysis
Last updated: June 12, 2026 3:16 PM ET
Data refreshes hourly during market hours. Next update: 4:16 PM
Data refreshes hourly during market hours. Next update: 4:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is THC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Paola M Arbour
SELL
6500 shares
2026-03-11
Thomas W Arnst
SELL
8000 shares
2026-03-09
R. Scott Ramsey
SELL
8017 shares
2026-03-02
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
HCA
HCA Healthcare, Inc. |
BUY
25 analysts |
$507 | 61 BUY |
|
EHC
Encompass Health Corp |
STRONG BUY
12 analysts |
$141 | 53 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
11 analysts |
$22 | 54 HOLD |
|
CON
Concentra Group Holdings… |
STRONG BUY
8 analysts |
$32 | 65 BUY |
|
ADUS
Addus HomeCare Corporati… |
STRONG BUY
11 analysts |
$133 | 58 HOLD |
Advanced THC Option Strategies
Professional options setups generated by AI based on today's THC price and gamma walls.
